Weighing Antitumor Immunity against Life-threatening Myocarditis from Immune-Checkpoint Inhibitors.

In this issue of Cancer Discovery, Salem and colleagues report a combination therapy for immune-checkpoint inhibitor (ICI) myocarditis using high-dose glucocorticoids, abatacept, and the JAK inhibitor ruxolitinib. The apparent efficacy of their strategy and an accompanying animal model provide further evidence for common immune mechanisms underlying ICI toxicities. See related article by Salem et al., p. 1100 (2).